Abstract
Colorectal cancer (CRC) is one of the most common malignancies worldwide, and new treatment strategies for CRC are required because of the existing chemotherapy resistance. Iron chelators, which have been used widely for the treatment of iron-overload disease, were reported to exert anti-proliferative effects in cancer. However, the role of iron chelation in CRC was largely unknown. In this study, we found that the iron chelator DFO inhibited CRC cell growth significantly. In addition, the gene expression profile was greatly changed by DFO treatment, and many cell growth-related genes were dysregulated. Further study showed that DFO induced a significant increase in global histone methylation in CRC cells. However, the levels of histone methyltransferases and histone demethylases did not change in response to DFO treatment, implying that the enzymatic activity of these enzymes might be regulated by iron chelation. In conclusion, this study reveals a novel role for DFO in CRC cell growth, and is the first to demonstrate that global histone methylation is modulated by iron chelation in CRC cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benard A et al (2014) Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early-stage colon cancer. BMC Cancer 14:531. https://doi.org/10.1186/1471-2407-14-531
Berry WL, Kim TD, Janknecht R (2014) Stimulation of beta-catenin and colon cancer cell growth by the KDM4B histone demethylase. Int J Oncol 44:1341–1348. https://doi.org/10.3892/ijo.2014.2279
Brard L, Granai CO, Swamy N (2006) Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol Oncol 100:116–127. https://doi.org/10.1016/j.ygyno.2005.07.129
Chen H, Costa M (2009) Iron- and 2-oxoglutarate-dependent dioxygenases: an emerging group of molecular targets for nickel toxicity and carcinogenicity. Biometals 22:191–196. https://doi.org/10.1007/s10534-008-9190-3
Chen H, Ke Q, Kluz T, Yan Y, Costa M (2006) Nickel ions increase histone H3 lysine 9 dimethylation and induce transgene silencing. Mol Cell Biol 26:3728–3737. https://doi.org/10.1128/MCB.26.10.3728-3737.2006
Chervona Y, Costa M (2012) The control of histone methylation and gene expression by oxidative stress, hypoxia, and metals. Free Radic Biol Med 53:1041–1047. https://doi.org/10.1016/j.freeradbiomed.2012.07.020
Edwards BK et al (2010) Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544–573. https://doi.org/10.1002/cncr.24760
Eisenstein RS (2000) Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr 20:627–662. https://doi.org/10.1146/annurev.nutr.20.1.627
Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8:286–298. https://doi.org/10.1038/nrg2005
Ferlay J et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. https://doi.org/10.1002/ijc.29210
Gezer U, Yoruker EE, Keskin M, Kulle CB, Dharuman Y, Holdenrieder S (2015) Histone methylation marks on circulating nucleosomes as novel blood-based biomarker in colorectal cancer. Int J Mol Sci 16:29654–29662. https://doi.org/10.3390/ijms161226180
Hann HW, Stahlhut MW, Blumberg BS (1988) Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res 48:4168–4170
Hann HW, Stahlhut MW, Menduke H (1991) Iron enhances tumor growth. Observation on spontaneous mammary tumors in mice. Cancer 68:2407–2410
Hickok JR, Vasudevan D, Antholine WE, Thomas DD (2013) Nitric oxide modifies global histone methylation by inhibiting Jumonji C domain-containing demethylases. J Biol Chem 288:16004–16015. https://doi.org/10.1074/jbc.M112.432294
Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692. https://doi.org/10.1016/j.cell.2007.01.029
Ke Q, Davidson T, Chen H, Kluz T, Costa M (2006) Alterations of histone modifications and transgene silencing by nickel chloride. Carcinogenesis 27:1481–1488. https://doi.org/10.1093/carcin/bgl004
Kondo Y, Shen L, Issa JP (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 23:206–215
Liu Y et al (2013) An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer. Gut 62:571–581. https://doi.org/10.1136/gutjnl-2011-301059
Marques-Gallego P, den Dulk H, Backendorf C, Brouwer J, Reedijk J, Burke JF (2010) Accurate non-invasive image-based cytotoxicity assays for cultured cells. BMC Biotechnol 10:43. https://doi.org/10.1186/1472-6750-10-43
Mosammaparast N, Shi Y (2010) Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem 79:155–179. https://doi.org/10.1146/annurev.biochem.78.070907.103946
Panczyk M (2014) Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol 20:9775–9827. https://doi.org/10.3748/wjg.v20.i29.9775
Salis O, Bedir A, Kilinc V, Alacam H, Gulten S, Okuyucu A (2014) The anticancer effects of desferrioxamine on human breast adenocarcinoma and hepatocellular carcinoma cells. Cancer Biomark 14:419–426. https://doi.org/10.3233/CBM-140422
Tokunaga R et al (2016) The prognostic significance of histone lysine demethylase JMJD3/KDM6B in colorectal cancer. Ann Surg Oncol 23:678–685. https://doi.org/10.1245/s10434-015-4879-3
Torti SV, Torti FM (2013) Iron and cancer: more ore to be mined. Nat Rev Cancer 13:342–355. https://doi.org/10.1038/nrc3495
Wu T, Sempos CT, Freudenheim JL, Muti P, Smit E (2004) Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 14:195–201. https://doi.org/10.1016/S1047-2797(03)00119-4
Xiao M et al (2012) Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 26:1326–1338. https://doi.org/10.1101/gad.191056.112
Xu W et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30. https://doi.org/10.1016/j.ccr.2010.12.014
Yamasaki T, Terai S, Sakaida I (2011) Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med 365:576–578. https://doi.org/10.1056/NEJMc1105726
Yokoyama Y et al (2013) Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo. Cancer Sci 104:889–895. https://doi.org/10.1111/cas.12166
Zacharski LR et al (2008) Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 100:996–1002. https://doi.org/10.1093/jnci/djn209
Zhang W et al (2014) Deferoxamine enhances cell migration and invasion through promotion of HIF-1alpha expression and epithelial–mesenchymal transition in colorectal cancer. Oncol Rep 31:111–116. https://doi.org/10.3892/or.2013.2828
Zhou X, Li Q, Arita A, Sun H, Costa M (2009) Effects of nickel, chromate, and arsenite on histone 3 lysine methylation. Toxicol Appl Pharmacol 236:78–84. https://doi.org/10.1016/j.taap.2009.01.009
Zhu W-G et al (2004) 5-Aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem 279:15161–15166. https://doi.org/10.1074/jbc.M311703200
Acknowledgements
This work was supported by National Natural Science Foundation of China Grant 81702788 and Beijing Natural Science Foundation Grant 7164305.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Cao, LL., Liu, H., Yue, Z. et al. Iron chelation inhibits cancer cell growth and modulates global histone methylation status in colorectal cancer. Biometals 31, 797–805 (2018). https://doi.org/10.1007/s10534-018-0123-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10534-018-0123-5